Skin Microbiome in Dermatologic Disorders

Abstract

The skin microbiome, a dynamic community of microorganisms residing on the human skin, plays a pivotal role in maintaining cutaneous health and modulating disease. Recent advances in metagenomics and molecular microbiology have elucidated the intricate relationship between the skin\'s microbial inhabitants and dermatologic disorders such as atopic dermatitis, psoriasis, acne, and rosacea. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical implications, and management of skin microbiome alterations in dermatology, emphasizing recent guideline updates and emerging therapeutic modalities. Understanding these mechanisms is crucial for clinicians aiming to leverage microbiome-targeted interventions in patient care.

Introduction

The human skin serves as the primary barrier between the body and the external environment, hosting a vast array of commensal, symbiotic, and occasionally pathogenic microorganisms. This microbiome encompasses bacteria, fungi, viruses, and mites, each contributing to the cutaneous ecosystem\'s homeostasis. Disruption of this balance, termed dysbiosis, is increasingly recognized as a central factor in the pathogenesis of multiple dermatologic disorders. The advent of high-throughput sequencing technologies has revolutionized our understanding, allowing precise characterization of microbial shifts associated with disease states. This review aims to provide clinicians with an updated, evidence-based analysis of the skin microbiome\'s role in dermatologic disorders, integrating mechanisms, clinical presentations, diagnostic considerations, and therapeutic strategies.

Epidemiology / Disease Burden

Dermatologic disorders with underlying microbiome dysregulation, including atopic dermatitis (AD), psoriasis, acne vulgaris, and rosacea, are among the most prevalent skin diseases globally. For instance, AD affects up to 20% of children and 3% of adults, with higher prevalence in industrialized nations, correlating with shifts in microbial diversity. Acne impacts approximately 85% of adolescents, while psoriasis has a global prevalence of 2–3%. These conditions impose significant morbidity, affecting quality of life and healthcare utilization. Epidemiological studies increasingly demonstrate that urbanization, antibiotic overuse, and altered hygiene practices contribute to global variations in skin microbiome composition, thereby influencing disease incidence and severity.

Pathophysiology

The skin microbiome interacts with the innate and adaptive immune system, influencing barrier function, inflammation, and tolerance. In AD, Staphylococcus aureus colonization predominates during flares, producing superantigens and proteases that exacerbate barrier dysfunction and immune activation. Conversely, reductions in commensal coagulase-negative staphylococci (e.g., S. epidermidis) impair antimicrobial peptide production. In psoriasis, microbial diversity is diminished, with increased Streptococcus and Malassezia species implicated in immune dysregulation via T helper 17 (Th17) pathways. Acne is characterized by shifts in Cutibacterium acnes phylotypes, with disease-associated strains promoting follicular inflammation. Rosacea exhibits increased Demodex mite density and altered bacterial profiles, contributing to chronic inflammation. Dysbiosis leads to aberrant signaling through toll-like receptors and cytokine release, perpetuating disease processes.

Risk Factors

Host genetics, immune status, age, environment, and lifestyle profoundly influence the skin microbiome. Genetic predispositions, such as filaggrin mutations in AD, compromise barrier integrity, facilitating pathogenic colonization. Immunosuppression, either iatrogenic or disease-related, alters microbial equilibrium and increases susceptibility to opportunistic infections. Environmental factors, including climate, humidity, and urbanization, affect microbial diversity. Topical and systemic antibiotics disturb commensal populations, predisposing to dysbiosis. Hygiene practices overcleansing or use of harsh products also disrupt the microbiome. Dietary patterns and hormonal changes, particularly during adolescence, contribute to microbial shifts relevant in acne.

Clinical Features

Microbiome-related dermatologic disorders manifest with characteristic phenotypes. AD presents with pruritic, eczematous lesions, often secondarily infected due to S. aureus dominance. Psoriatic plaques are erythematous and scaly, with microbial imbalances correlating with disease activity. In acne, inflammatory papules, pustules, and nodules reflect Cutibacterium-driven follicular inflammation. Rosacea features persistent erythema, telangiectasia, and papulopustular eruptions, often exacerbated by Demodex overgrowth. Secondary infections and poor wound healing are common in dysbiotic conditions, emphasizing the clinical relevance of microbial surveillance.

Diagnosis

Diagnosis of microbiome-related skin diseases remains primarily clinical, supported by history and physical examination. However, molecular diagnostic tools, including next-generation sequencing (NGS), 16S rRNA gene analysis, and quantitative PCR, enable precise characterization of microbial communities. These methods facilitate the identification of dysbiosis patterns and guide therapeutic decisions, particularly in refractory or atypical cases. Traditional culture techniques remain valuable for identifying dominant pathogens, especially in infected lesions. Emerging diagnostic modalities, such as metagenomic shotgun sequencing, offer comprehensive profiling and may soon inform routine clinical practice.

Treatment & Management

Management strategies target both disease control and restoration of microbial balance. In AD, topical corticosteroids, calcineurin inhibitors, and targeted antibiotics (e.g., mupirocin) are combined with barrier repair measures. Recent studies support the adjunctive use of bleach baths, emollients, and probiotic-containing topicals to modulate the microbiome. Psoriasis management centers on immunomodulators (biologics, methotrexate) with consideration for antifungals if Malassezia is implicated. Acne therapy includes topical retinoids, benzoyl peroxide, and antibiotics, with the latter used judiciously to avoid resistance and dysbiosis. Rosacea treatment employs topical metronidazole, ivermectin, and systemic tetracyclines, targeting both microbial and inflammatory pathways. Patient education on gentle skin care and avoidance of microbiome-disrupting practices is essential.

Recent Advances / Emerging Therapies

Emerging therapies focus on targeted microbiome modulation. Topical probiotics, prebiotics, and postbiotics aim to restore commensal populations and enhance barrier function. Bacteriophage therapy, designed to selectively eliminate pathogenic bacteria such as S. aureus, is under investigation in AD and other conditions. Microbiome transplantation, including the transfer of healthy skin flora, has shown promise in early trials. Advances in synthetic biology enable engineering of skin-resident bacteria to produce anti-inflammatory or antimicrobial compounds. Small-molecule agents targeting quorum sensing or microbial virulence factors represent additional avenues for intervention. These approaches are supported by growing clinical trial data, informing future therapeutic algorithms.

Guideline Recommendations

Recent clinical guidelines emphasize the importance of microbiome preservation in dermatologic care. The American Academy of Dermatology and European Dermatology Forum recommend limiting unnecessary antibiotic use, promoting barrier repair, and considering adjunctive therapies that support microbial diversity. For AD, guidelines endorse bleach baths and barrier-enhancing emollients. Psoriasis and acne management protocols highlight the judicious use of antimicrobials and consideration of microbial contributions to disease. Emerging recommendations advocate for integration of molecular diagnostics and participation in clinical trials assessing microbiome-based therapies.

Conclusion

The skin microbiome is integral to cutaneous health and disease. Disruption of microbial equilibrium is implicated in the pathogenesis of numerous dermatologic disorders, with significant clinical and therapeutic implications. Advances in microbiome research have fostered a paradigm shift in diagnosis and management, enabling precision medicine approaches that target both host and microbial factors. Ongoing research and clinical trials will continue to refine our understanding, offering novel strategies for disease prevention and treatment. Clinicians should remain abreast of evolving evidence and incorporate microbiome-preserving practices into patient care for optimal outcomes.